APN 401

Drug Profile

APN 401

Alternative Names: APN401; siRNA-transfected peripheral blood mononuclear cells - Apeiron

Latest Information Update: 07 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Small interfering RNA
  • Mechanism of Action CBLB protein expression inhibitors; RNA interference; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Mar 2017 Wake Forest University Health Sciences and National Cancer Institute plan a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in USA (NCT03087591)
  • 04 Oct 2016 APEIRON Biologics plans a phase II trial for Cancer
  • 16 Feb 2016 Apeiron in-licenses technology related to inhibition of Cbl-b from Columbia University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top